Presentations & Publications

Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human

UPLOADED:

January 4, 2011

High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action

UPLOADED:

July 9, 2009

The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix

UPLOADED:

May 3, 2009

An Anti-VEGFR2/Flk-1 Listeria monocytogenes Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu Positive Breast Tumors in a Mouse Model

UPLOADED:

May 1, 2009

An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.

UPLOADED:

May 1, 2009

A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors

UPLOADED:

February 1, 2009

Multiple Effector Mechanisms Induced by Recombinant Listeria monocytogenes Anticancer Immunotherapeutics

UPLOADED:

January 4, 2009

Construction and Characterization of an Attenuated Listeria monocytogenes Strain for Clinical Use in Cancer Immunotherapy

UPLOADED:

January 4, 2009

Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors

UPLOADED:

September 26, 2008

Development of a Listeria monocytogenes based vaccine against prostate cancer

UPLOADED:

February 14, 2008

Presentations & Publications

Presentations & Publications

Mailing List

Follow Us